Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Abstract: Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.

Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

Abstract: Piglet feed is supplemented with anti-E. coli K88 antibody-containing egg powder having a titer of the K88 antibodies of at least 1/256,000 as a means of improving growth performance of piglets.

Abstract: This invention relates to novel reagent conjugates and a novel multi-step process for delivering active compounds to target analytes of interest in a patient for diagnostic and therapeutic purposes. According to the process, two novel reagents are bound to each other by linkage of the sequence-specific components they contain. The first reagent, which is comprised of a target recognition component and a first sequence-specific component, is introduced into the patient and allowed to achieve maximal localization on the target cells. The second reagent, which is comprised of an active compound component and a second sequence-specific component is then introduced into the patient, thereby forming a complex with the first reagent via the recognition and binding of the sequence-specific components of the two reagents to form the reagent conjugate of the invention. The active compound component is thereby efficiently and specifically delivered to the target analyte.

Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.

Abstract: The invention describes HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof. The genes which are described are the tat, nef and rev genes. Consensus amino acid sequences are also disclosed. The invention also relates to a vaccine including two or more of the nucleotide sequences, and nucleotide sequences from the pol and/or gag genes of HIV-1.

Abstract: An object of the present invention is to search and identify novel antifungal proteins capable of inhibiting the growth of plant pathogenic microorganisms including Magnaporthe grisea and Rhizoctonia solani causing two major rice diseases at relatively low concentrations, and further to clone a gene for said protein. The present invention provides an antifungal protein which can be obtained from fraction(s) precipitated by ammonium sulfate precipitation using an aqueous extract from Pleurotus cornucopiae, wherein said protein has an antifungal activity against at least rice blast, and exhibits existence of a component having a molecular weight of about 15 kDa as determined by SDS-PAGE method; a gene encoding said protein and uses thereof.

Abstract: There is provided a HBV precore protein having an ability of forming particles, and a means for determining it. A novel HBV precore protein that forms the virus (like) particles of HBV was identified. The present invention provides this novel HBV precore protein. Furthermore, there are provided core-like particles and virus-like particles formed by this HBV precore protein. These virus-like particles can be used for vaccines and therapeutic agents. The present invention also provides a method of determining the HBV precore protein and a method of determining the anti-HBV precore protein antibody.

Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.

Abstract: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.

Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.

Abstract: A preparation, in particular a cosmetic preparation, in the form of a workable paste which is present in the form of a W/O emulsion and which is suitable for cosmetic uses, in particular in the area of decorative cosmetics for coloring and improving the skin, the lips and the eyelids. It is also suitable as a fixing for lipstick, as lip care, as a skin care foundation or as a sun protection agent. It is preferably in the form of a water-in-silicone emulsion. It contains a wax, a suitable emulsifier, a volatile silicone oil, a moistening agent, a solid phase and water. In addition it may also contain the additives and adjuvant substances which are approved and usual in cosmetics. Processes for the production of the preparation are also described.

Abstract: Annoying insects are controlled by attaching an insect control device to the body of the animal to be treated. The insect control device is a molded article, preferably in the form of an ear tag, which has been formed from a powder mixture of coumaphos and diazinon, polyvinyl chloride, and a plasticizer. The coumaphos and diazinon are generally used in an amount that would prolong the insecticidal activity without detracting from the suitability of the device.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: The present invention relates generally to radiation-resistant medical devices which contain polymer regions for release of therapeutic agents. The present invention also relates to radiation-resistant block copolymer materials for use in connection with insertable or implantable medical devices. The radiation-sterilized medical device comprise (a) a release region and (b) at least one therapeutic agent and the release region comprises a radiation resistant copolymer that includes (i) a low Tg hydrocarbon polymer block and (ii) one or more high Tg polymer blocks.

Abstract: The present disclosure relates to devices methods for the reverse transport of lipids such as cholesterols for the treatment diseases and conditions caused by vulnerable plaques. The devices can reduce or eliminate vulnerable plaques by transporting the plaques away from their location.

Abstract: Biocompatible terpolymers are manufactured to include a zwitterionic monomer, an alkoxy acrylate monomer, and a hydrophobic monomer. The alkoxy acrylate monomer can be a 2-methoxyethyl methacrylate (MOEMA) or a 2-methoxyethyl methacrylate (EOEMA). Alternatively, the alkoxy acrylate can be 2-methoxyethyl acrylate (MOEA) or 2-methoxyethyl acrylate (EOEA). The alkoxy acrylate monomers advantageously give the zwitterionic copolymers greater ductility, strength, and toughness while maintaining a desired amount of hydrophilicity. The improved toughness allows the zwitterionic copolymers to be processed without cross-linking, which improves the elongation properties of the zwitterionic copolymer, and reduces the risk of cracking during use.

Abstract: Living cellular material is encapsulated or placed in a protective material (cell protector) which is biocompatible, biodegradable and has a three-dimensional form. The three dimensional form is incorporated into a matrix that maybe implanted in vivo, ultimately degrade and thereby by replaced by living cell generated material.

Abstract: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.

Abstract: A biocompatible biological component is provided comprising a membrane-mimetic surface film covering a substrate. Suitable substrates include hydrated substrates, e.g. hydrogels which may contain drugs for delivery to a patient through the membrane-mimetic film, or may be made up of cells, such as islet cells, for transplantation. The surface may present exposed bioactive molecules or moieties for binding to target molecules in vivo, for modulating host response when implanted into a patient (e.g. the surface may be antithrombogenic or antiinflammatory) and the surface may have pores of selected sizes to facilitate transport of substances therethrough. An optional hydrophilic cushion or spacer between the substrate and the membrane-mimetic surface allows transmembrane proteins to extend from the surface through the hydrophilic cushion, mimicking the structure of naturally-occurring cells.

Abstract: Presents novel hollow fiber shaped organic nanotubes that can be easily produced in a short time span and also have a broad range of utility. An N-glycoside type glycolipid represented by the general formula (1) shown below. G-NHCO—R??(1) (In the formula, G represents a saccharide radical other than a hemiacetal hydroxyl group bonded to the anomer carbon atom of the saccharide, and R represents an unsaturated hydrocarbon group containing ten to 39 carbon atoms.) This molecule self-aggregates and forms hollow fiber shaped organic nanotubes in water when this N-glycoside type glycolipid is dissolved, allowed to cool gradually and allowed to stand undisturbed at room temperature. The average external diameter of the nanotubes is from 70 nm to 500 nm and the average internal diameter (average diameter of the cavity) is from 40 nm to 300 nm.

Abstract: A soft gelatin capsule and method to deliver an efficable dose of Lagerstroemia speciosa L. (marketed by Soft Gel Technologies under the trademark Glucosol™) for the assistance and maintenance of moderate weight loss through blood sugar maintenance. The product relies on the effects of corosolic acid on blood sugar levels to derive a healthy weight loss effect for Type II diabetics (non-insulin dependent) and healthy non-diabetics and the improved absorption of an oil based delivery system. The product provides safe and sustainable weight loss when combined with a restricted calorie diet and regular exercise. Its benefits include improvement of cardiovascular health, normalized blood sugar levels, and improved physical appearance with the positive psychological effects associated with successful and safe weight loss/maintenance.

Abstract: A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.

Abstract: Disclosed are amorphous solid dispersion formulations comprising 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide.

Abstract: A tablet for the controlled release of a pharmaceutically active ingredient. The tablet is in the form of coated DST's and MLDST's so that immediate release or time-delayed release can be achieved. Further, such extended release DST's and MLDST's may provide zero order or first order extended release kinetics depending on the excipients and types of pharmaceutically active ingredients in the tablet formulation. The time delay coating is made of high molecular weight water soluble polymers so that dose dumping can be minimized even when the hydrated surface of the DST and MLDST peels off. A second coating of low molecular weight water soluble polymer with a pharmaceutically active ingredient dispersed therein provides for pulsatile release.

Abstract: Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

Abstract: Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.

Abstract: Disclosed is a medical device (5) and more particularly, an implantable biomaterial. The biomaterial comprises a radiopaque (22) collagenous biomaterial (10).

Abstract: A method of manufacture of a liquid pesticide containing copper. A first step involves forming of a solidified water soluble copper-borate complex. A second step involves dissolving the solidified water soluble copper-borate complex in water, until the water contains a concentration of at least 0.02% by weight of copper.

Abstract: The subject invention provides a process and apparatus for making “enhanced water” that is uniquely suitable for improving circulation, hydration and insulin usage with diabetics. Thus, in a preferred embodiment, the invention provides methods for the treatment and/or prevention of diabetes as well as the prevention or delay in development of diabetes-related complications, conditions or diseases.

Abstract: Present invention provides an efficient way of enhancing male erectile function, without the fear of unknown long-term ill-effect as a result of taking medication orally. The additive of present invention can be used by condom manufacturers directly as part of the lubricant coating. The composition of the additive pursuant to present invention will cause the dilating and expansion of arteries sending blood to the chambers of corpora cavernosa and corpus spongiosum, and at the same time, cause the restricting and contracting of veins that take blood away. As a result, the hardness of penile erection is increases. Particularly, the staying power is enhanced and time of erection is prolonged, leading to increased sexual intercourse time and better sexual satisfaction.

Abstract: Extracts from an indigenous Jamaican plant that exhibit an anti-tumor activity and/or an anti-inflammatory activity and, more particularly, an extract of Jamaican Ball Moss (Tillandsia Recurvata) that has a therapeutic pharmacological activity, in particular an anti-cancerous activity by inducing tumorous cell death by apoptosis, and active compounds isolated thereof are described. Furthermore, methods for the extraction of the extracts are disclosed. Also, a pharmaceutical composition or product for the treatment of cancer which includes an effective amount of the described extract or an active compound thereof, a therapeutic compound and optionally a pharmaceutical acceptable carrier are described.

Abstract: A natural oriental medicinal composition for the promotion of hair growth is provided. The oriental medicinal composition includes a black bean extract, a tangerine extract, a potato extract, a pine needle extract and a quartzite powder. Since the oriental medicinal composition includes crude drugs extracted from natural substances that can prevent hair loss, it is effective for hair growth and has ensured biostability. Particularly, the oriental medicinal composition allows newborn hair to grow in the form of stiff hair.

Abstract: Extra-cellular product anti-biofouling against marine invertebrates which are common to the biofouling, which contains an extract of the supernatant of an Alteromonas sp. Culture. Anti-biofouling composition, comprising said extra-cellular product and a biopolymer. The use of said extra-cellular product for preparing a composition useful for inhibiting the marine micro- and macro-biofouling, and the process for preparing said extra-cellular product.

Abstract: Amorphous water-soluble calcium citrate salts having a mole ratio of calcium to citrate of less than 2.5:2, and powdered beverage mixes and liquid compositions fortified with these amorphous water-soluble calcium citrate salts as a calcium source, are provided. Liquid compositions fortified with calcium citrate according to this invention have superior dispersability, solubility, appearance, and storage stability. These liquid compositions are prepared by new methods that provide and preserve a stable amorphous character in the dry powdered product salts. The present invention also is directed to a method of administering such calcium citrate-fortified liquid compositions to increase the dietary calcium intake in individuals.

Abstract: Oil resistant package material and packages prepared therefrom have cyclodextrin incorporated in or adjacent to a film layer of the package to reduce the permeation of oil through the package material, and particularly out of the package. The film layer comprises a polymer that coordinates or bonds with a cyclodextrin compound in an amount sufficient to reduce the permeation of oil through the film layer as compared to a like film layer that does not contain cyclodextrin.

Abstract: An animal feed is provided that employs a substantially indigestible cation exchanger capable of binding ammonium cations and an acidogenic substance to acidify an animal's manure and thereby create ammonium cations that can be bound by the cation exchanger. The animal feed reduces ammonia emissions from manure produced by animals fed the animal feed compared to the emissions obtained from manure when an acidogenic substance is fed alone and compared to the emissions obtained from manure when a cation exchange capacity material is fed alone. According to another aspect of the present invention, a method of lowering ammonia emissions from manure is provided. The present invention also provides a method for reducing soluble phosphorus levels in manure and a method for reducing total phosphorus levels in manure.

Abstract: A process for preparing butter milk and/or butter serum, which comprises decreasing the dissolved oxygen concentration of at least one selected from the group consisting of milk, a milk product, butter milk and butter serum, followed by heating, and optionally fractionizing the heated product.

Abstract: Methods for preparing cheese are provided that involve combining a slurry with a cheese precursor to form an admixture that is subsequently processed to form the cheese product. The slurry typically includes a liquid such as water, milk and/or cream and one or more ingredients that are useful for inclusion in the final cheese product. Systems for preparing such slurries and cheese products are also provided.

Abstract: A process for preparing an instant beverage is provided which includes heating a dried soluble coffee under sufficient pressure thereby forcing gas into internal voids of the dried coffee. The heated dried soluble coffee is cooled and depressurized to produce a dried soluble coffee having internal voids filled with pressurized gas. An instant dry beverage comprising soluble coffee having internal voids filled with pressurized gas is also provided, and this product is advantageous in that it produces a beverage with foam on its surface when reconstituted.

Abstract: A process for enhancing polyphenolics content of beverages brewed from polyphenolic containing, processed beverage substrate by pre-soaking substrate (coffee beans, for example) before roasting and then quenching the substrate after processing with the liquid in which the substrate was first “pre-soaked.” Beverages produced from the treated substrate exhibit substantially increased polyphenolics content, when compared to conventionally processed beverage substrate of the same nature and processing.

Abstract: A method for altering a coffee source component profile of an aged coffee source to mimic a target coffee component profile of a non-aged coffee source, wherein the aged coffee source and the non-aged coffee each comprise multiple taste contributing acids.

Abstract: A method for altering a coffee source component profile of a coffee source to mimic a target coffee component profile of a target coffee, wherein the coffee source and the target coffee each comprise multiple taste contributing acids.

Abstract: The invention provides olive-derived hydroxytyrosol. According to one aspect of the invention, vegetation water is collected from olives. Acid is added to stabilize the vegetation water and prevent fermentation. The mixture is incubated to allow oleuropein to convert to hydroxytyrosol, and then fractionated to separate hydroxytyrosol from other components. The hydroxytyrosol is useful as a therapeutic and anti-oxidant for a variety of health purposes, including for the treatment of skin damage. In addition, the hydroxytyrosol is useful as a natural anti-bacterial, anti-viral and fungicidal product for agricultural and pest control applications.

Abstract: The present invention provides a method for the preparation of high liquid oil margarine in the form of a water-in-oil emulsion wherein selected phospholipids (for example, PC, PE and lyso-PC/PE) play an important role in stabilizing the margarine. The total fat content of said high liquid oil margarine is made up of a minimum of about 96% liquid oil and a maximum of about 4% added hard fat and phospholipids. The method comprises preparing a water-in-oil emulsion by blending an aqueous phase with oil phase at a temperature above the crystallization temperature of the added hard fat and reducing said temperature until hard fat crystallization occurs, and supercooling in heat exchanger to obtain a high liquid oil margarine. The method of the invention uses selected phospholipids and the use of heat exchanger “votator” for fat crystal nucleation and provides a margarine comprising very low levels of saturated fats and virtually no trans fatty acids.

Abstract: An egg-based material that includes an egg-based substance, a water-absorbent thickener distributed throughout the egg-based material, and pieces of supplemental food distributed throughout the egg-based material, where the egg-based substance includes a natural liquid egg component and the water-absorbent thickener is effective to maintain distribution of the pieces of supplemental food throughout the egg-based material.

Abstract: The invention is to products for enhancing the nutrient value of distillers, brewers or fermenters grain byproducts using an injector or mixer to add predetermined amounts of nutrients to the grains. The byproduct nutrient obtained is heated, dried and/or extruded to increase the ruminant bypass protein of the nutrient product.

Abstract: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is placed on the surface of a medical device, then one component of the mixture or alloy is generally removed without generally removing the other components of the mixture or alloy. In some embodiments, a porous layer is adapted for bonding non-metallic coating, including drug eluting polymeric coatings. A porous layer may have a random pore structure or an oriented or directional grain porous structure. One embodiment of the invention relates to medical devices, including vascular stents, having at least one porous layer adapted to resist stenosis or cellular proliferation without requiring elution of therapeutic agents.

Abstract: The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.